SwitzerlandSwitzerland

Roche reports positive preliminary Phase III results in metastatic melanoma

20.01.2011

Basel – Roche AG’s orally ATP-competitive BRAF(V600E) kinase blocker RG7204 (PLX4032, RO5185426) has achieved secondary endpoint in an ongoing open label Phase III study comparing overall survival in 675 treatment-naive metastatic melanoma patients treated with either RO5185426 or the DNA alkylating chemotherapeutic dacarbazine. After one year of treatment, patients who received the inhibitor of BRAF signalling lived longer without their disease progression (progression-free survival) compared to the dacarbazine arm. Additionally, melanoma patients receiving twice daily 960 mg of RO5185426 lived longer than patients receiving one 1000 mg injection every 3 weeks of the current standard of care, according to preliminary data. The BRIM 3 trail with RO5185426 (NCT01006980) is to be completed by 2014. Patients who carry a BRAF(V600E) mutation identified by Roche’s Cobas companion diagnostics test show permanent activation of MAPK and ERK that results in tumour cell proliferation. The mutated BRAF protein is found in about half of all cases of metastatic melanoma. RO5185426 blocks BRAF(V600E) kinase signalling in the cell. The compound is being co-developed with Plexxikon Inc since 2006.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/roche-reports-positive-preliminary-phase-iii-results-in-metastatic-melanoma.html

Product of the week

Products

Events

All Events

Current issue

All issues